Daily case rate and 7day moving average rate for the medical laboratory services staff. حسب Kerry Sidwell Wilson (12890013)

الموضوعات:

COVID-19 confirmed cases, COVID-19 confirmed deaths and vaccinations on the Navajo Nation. حسب Wilfred F. Denetclaw (13199874)

Comparison of case and control characteristics. حسب Imelda Sonia Nzinnou Mbiaketcha (14670572)

الموضوعات:

Impact of mass gatherings (after the lift of POGGR) on the number of new cases of COVID-19 (with intervention point changed). حسب Pengyu Zhu (1819939)

الموضوعات:

The numerical solution of model (1) for infected compartment vs. time with different scenarios of Phase 2 in the First Case: 1^<i>st</i> scenario, no lockdown is implemented; 2^<i>nd</i> scenario, no lockdown while <i>SD</i> increases; 3^<i>rd</i> scenario, lockdown increases; 4^<i>th</i> scenario, <i>SD</i> increases; 5^<i>th</i> scenario, lockdown decreases; 6^<i>th</i> scenario, <i>SD</i> decreases; 7^<i>th</i> scenario, lockdown and <i>SD</i> increases; 8^<i>th</i> scenario, lockdown decreases and <i>SD</i> increases; 9^<i>th</i> scenario, <i>ρ</i> is the same as in Phase 1; 10^<i>th</i> scenario, <i>ρ</i> is the same as in Phase 1 while <i>SD</i> increases; 11^<i>th</i> scenario, <i>ρ</i> = 0.75 in all Phase 2; 12^<i>th</i> scenario, <i>ρ</i> = 0.75 while <i>SD</i> increases. حسب Sara K. Al-Harbi (12418482)

"…<p>The numerical solution of model <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0265779#pone.0265779.e002" target="_blank">(1)</a> for infected compartment vs. time with different scenarios of Phase 2 in the First Case: 1^<i>st</i> scenario, no lockdown is implemented; 2^<i>nd</i> scenario, no lockdown while <i>SD</i> increases; 3^<i>rd</i> scenario, lockdown increases; 4^<i>th</i> scenario, <i>SD</i> increases; 5^<i>th</i> scenario, lockdown decreases; 6^<i>th</i> scenario, <i>SD</i> decreases; 7^<i>th</i> scenario, lockdown and <i>SD</i> increases; 8^<i>th</i> scenario, lockdown decreases and <i>SD</i> increases; 9^<i>th</i> scenario, <i>ρ</i> is the same as in Phase 1; 10^<i>th</i> scenario, <i>ρ</i> is the same as in Phase 1 while <i>SD</i> increases; 11^<i>th</i> scenario, <i>ρ</i> = 0.75 in all Phase 2; 12^<i>th</i> scenario, <i>ρ</i> = 0.75 while <i>SD</i> increases.…"

The numerical solution of model (1) for infected compartment vs. time with different scenarios of Phase 3 in the First Case: 1^<i>st</i> scenario, no lockdown is implemented; 2^<i>nd</i> scenario, no lockdown while <i>SD</i> increases; 3^<i>rd</i> scenario, lockdown increases; 4^<i>th</i> scenario, <i>SD</i> increases; 5^<i>th</i> scenario, lockdown decreases; 6^<i>th</i> scenario, <i>SD</i> decreases; 7^<i>th</i> scenario, lockdown and <i>SD</i> increases; 8^<i>th</i> scenario, lockdown decreases and <i>SD</i> increases; 9^<i>th</i> scenario, <i>ρ</i> is the same as in Phase 2; 10^<i>th</i> scenario, <i>ρ</i> is the same as in Phase 2 while <i>SD</i> increases. حسب Sara K. Al-Harbi (12418482)

"…<p>The numerical solution of model <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0265779#pone.0265779.e002" target="_blank">(1)</a> for infected compartment vs. time with different scenarios of Phase 3 in the First Case: 1^<i>st</i> scenario, no lockdown is implemented; 2^<i>nd</i> scenario, no lockdown while <i>SD</i> increases; 3^<i>rd</i> scenario, lockdown increases; 4^<i>th</i> scenario, <i>SD</i> increases; 5^<i>th</i> scenario, lockdown decreases; 6^<i>th</i> scenario, <i>SD</i> decreases; 7^<i>th</i> scenario, lockdown and <i>SD</i> increases; 8^<i>th</i> scenario, lockdown decreases and <i>SD</i> increases; 9^<i>th</i> scenario, <i>ρ</i> is the same as in Phase 2; 10^<i>th</i> scenario, <i>ρ</i> is the same as in Phase 2 while <i>SD</i> increases.…"

The numerical solution of model (1) for infected compartment vs. time with different scenarios of Phase 6 in the First Case: 1^<i>st</i> scenario, no lockdown is implemented; 2^<i>nd</i> scenario, no lockdown while <i>SD</i> increases; 3^<i>rd</i> scenario, lockdown increases; 4^<i>th</i> scenario, <i>SD</i> increases; 5^<i>th</i> scenario, lockdown decreases; 6^<i>th</i> scenario, <i>SD</i> decreases; 7^<i>th</i> scenario, lockdown and <i>SD</i> increases; 8^<i>th</i> scenario, lockdown decreases and <i>SD</i> increases; 9^<i>th</i> scenario, <i>ρ</i> is the same as in Phase 5; 10^<i>th</i> scenario, <i>ρ</i> is the same as in Phase 5 while <i>SD</i> increases. حسب Sara K. Al-Harbi (12418482)

"…<p>The numerical solution of model <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0265779#pone.0265779.e002" target="_blank">(1)</a> for infected compartment vs. time with different scenarios of Phase 6 in the First Case: 1^<i>st</i> scenario, no lockdown is implemented; 2^<i>nd</i> scenario, no lockdown while <i>SD</i> increases; 3^<i>rd</i> scenario, lockdown increases; 4^<i>th</i> scenario, <i>SD</i> increases; 5^<i>th</i> scenario, lockdown decreases; 6^<i>th</i> scenario, <i>SD</i> decreases; 7^<i>th</i> scenario, lockdown and <i>SD</i> increases; 8^<i>th</i> scenario, lockdown decreases and <i>SD</i> increases; 9^<i>th</i> scenario, <i>ρ</i> is the same as in Phase 5; 10^<i>th</i> scenario, <i>ρ</i> is the same as in Phase 5 while <i>SD</i> increases.…"

The modularity of the subcommunity of the COVID-19 clusters in Zhejiang Province. حسب Haocheng Wu (559031)

الموضوعات:

Diagram of eligible, included and excluded cases, and diagnostic cross tabulation. حسب David Goodman-Meza (4532713)

Risk of severe COVID-19 by age group for increased risk patients not accessing antiviral treatment— Mass General Brigham, June to December 2022. حسب Scott Dryden-Peterson (227433)

الموضوعات:

Equivalent elastic modulus of the capsule under case 1 and case 3. حسب Hongliang Zhang (149767)

Equivalent Poisson’s ratio of the capsule under case 1 and case 3. حسب Hongliang Zhang (149767)

Fig 1 - حسب Christian Karagiannidis (64152)

الموضوعات:

Estimated time-lags and case ascertainment for time-delay models fit to REACT-1 using the time series of daily cases. حسب Oliver Eales (11495186)

الموضوعات:

Characteristics of vaccinated population by anti-COVID-19 vaccine brand (27 December 2020–30 September 2021). حسب Cristina Morciano (9397154)

الموضوعات:

Case #5 حسب Bálint Lakatos (10535348)

Case #2 حسب Bálint Lakatos (10535348)

Risk of severe COVID-19 by WHO risk groups for increased risk patients not accessing antiviral treatment— Mass General Brigham, June to December 2022. حسب Scott Dryden-Peterson (227433)

الموضوعات:

Risk of severe COVID-19 by NIH prioritization tier for increased risk patients not accessing antiviral treatment— Mass General Brigham, June to December 2022. حسب Scott Dryden-Peterson (227433)

الموضوعات:

Case #4 حسب Bálint Lakatos (10535348)